Nebenwirkungen · Evista
Evista 60 mg film coated tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-088399 · Präparat HOS-083635
Rare cases of moderate increases in AST and/or ALT have been reported where a causal relationship to raloxifene can not be excluded. A similar frequency of increases was noted among placebo patients. In a study (RUTH) of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an additional adverse reaction of cholelithiasis occurred in 3.3 % of patients treated with raloxifene and 2.6 % of patients treated with placebo. Cholecystectomy rates for raloxifene (2.3 %) were not statistically significantly different from placebo (2.0 %).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-01T12:30:00Z · SHA-256 f4ce424f62210f59bcb50c6293efacced149e50104e46c80a22544ef7153a17d · Passage f06960ffc8ffe40bb9d8ed639e6bcefbf46fe1ddfcca69f055092c57aa1681d6 · Zeichen 6066–6649 im Abschnitt